A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Harriet S. Walter et al.|Journal of Clinical Oncology|2019Cited by 31
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.Udai Banerji, Robert H. Jones, Víctor Moreno et al.|Journal of Clinical Oncology|2019Cited by 20